BOSTON, February 10, 2025--Vertex Pharmaceuticals Incorporated ... stocks in the biotech industry that have moved in opposite directions so far this year: Vertex Pharmaceuticals (NASDAQ: VRTX ...

As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in startups focused on pain management and treatment. Turns out there’s quite a ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

“Today is an important day for the sickle cell community who have gone too long without treatments that address ... 1. Vertex was founded in 1989 and has its global headquarters in Boston ...

To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex ... in Boston, Massachusetts and San Francisco, California. To learn ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...

Cigna To Reform Prior Authorization, Provider Services In 2025 The Cigna Group will spend up to $150 million to reform its prior authorization, patient advocacy and provider services this year, CEO ...

During the earnings call, Kewalramani also said Vertex hit a big milestone in 2024, recording double-digit revenue growth for the 10th consecutive year. The Boston drugmaker's 2024 product revenue ...

That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...